Commercialization of Human Visceral Adipocytes

人内脏脂肪细胞的商业化

• 批准号: 6989857
• 负责人: YOLANDA Renee LEA-CURRIE
• 金额: $ 47.37万
• 依托单位: ZEN-BIO, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-01 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6989857
• 关键词: adipocytes; cell differentiation; clinical research; gene expression profiling; human tissue; microarray technology; molecular biology information system; technology /technique development; tissue /cell culture

DESCRIPTION (provided by applicant): The US is experiencing an epidemic rise in obesity and related co-morbidities such as type II diabetes. Epidemiological studies demonstrate that these co-morbidities are specifically correlated with visceral (intra-abdominal) fat deposition. To elucidate this association, a fully characterized and performance tested cultured human adipocyte cell system must be made available to researchers. The goal of the proposed work is to develop a commercially accessible, novel, well characterized cultured human visceral adipocyte cell system. Preliminary data indicate visceral adipocytes are distinct from subcutaneous adipocytes, requiring individualized culturing and assaying techniques. Phase II has three specific aims. I. Establish a protocol for differentiation of visceral preadipocytes into adipocytes. II. Develop a suite of assays necessary to provide quality control tests for the cultured cells. The assays will also be offered as a commercial contract research service utilizing the visceral cell system. III. Perform expression profiling of primary and cultured visceral adipocytes and preadipocytes in order to validate the cultured cell system. The completion of the research will result in a commercially accessible, performance tested, fully validated cultured human visceral adipocyte cell system. Availability of this system will open the door for large scale screening in cultured human visceral cells, provide a better understanding of the roles visceral adipose plays in disease development and provide a faster and less expensive path to drug development.

描述（由申请人提供）：美国的肥胖症和相关并发症（例如 II 型糖尿病）正在流行。流行病学研究表明，这些合并症与内脏（腹内）脂肪沉积特别相关。为了阐明这种关联，必须向研究人员提供经过充分表征和性能测试的培养人类脂肪细胞系统。拟议工作的目标是开发一种商业化的、新颖的、特征良好的培养人内脏脂肪细胞系统。初步数据表明内脏脂肪细胞与皮下脂肪细胞不同，需要个体化培养和检测技术。第二阶段有三个具体目标。 I. 建立内脏前脂肪细胞分化为脂肪细胞的方案。二.开发一套必要的分析方法，为培养细胞提供质量控制测试。这些检测还将作为利用内脏细胞系统的商业合同研究服务提供。三．对原代和培养的内脏脂肪细胞和前脂肪细胞进行表达谱分析，以验证培养的细胞系统。该研究的完成将产生一个可商业化、经过性能测试、经过充分验证的培养人内脏脂肪细胞系统。该系统的可用性将为培养的人类内脏细胞的大规模筛选打开大门，更好地了解内脏脂肪在疾病发展中的作用，并为药物开发提供更快、更便宜的途径。